Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct

被引:937
作者
Conway, KA [1 ]
Rochet, JC [1 ]
Bieganski, RM [1 ]
Lansbury, PT [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA
关键词
D O I
10.1126/science.1063522
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The substantia nigra in Parkinson's disease (PD) is depleted of dopaminergic neurons and contains fibrillar Lewy bodies comprising primarily alpha -synuclein. We screened a library to identify drug-like molecules to probe the relation between neurodegeneration and alpha -synuctein fibrilization. All but one of 15 fibril inhibitors were catecholamines related to dopamine. The inhibitory activity of dopamine depended on its oxidative ligation to alpha -synuctein and was selective for the protofibril-to-fibril conversion, causing accumulation of the alpha -synuctein protofibril. Adduct formation provides an explanation for the dopaminergic selectivity of alpha -synuctein-associated neurotoxicity in PD and has implications for current and future PD therapeutic and diagnostic strategies.
引用
收藏
页码:1346 / 1349
页数:4
相关论文
共 31 条
  • [1] Levodopa - Is toxicity a myth?
    Agid, Y
    [J]. NEUROLOGY, 1998, 50 (04) : 858 - 863
  • [2] Baba M, 1998, AM J PATHOL, V152, P879
  • [3] Chronic systemic pesticide exposure reproduces features of Parkinson's disease
    Betarbet, R
    Sherer, TB
    MacKenzie, G
    Garcia-Osuna, M
    Panov, AV
    Greenamyre, JT
    [J]. NATURE NEUROSCIENCE, 2000, 3 (12) : 1301 - 1306
  • [4] Cross-linking in adhesive quinoproteins: Studies with model decapeptides
    Burzio, LA
    Waite, JH
    [J]. BIOCHEMISTRY, 2000, 39 (36) : 11147 - 11153
  • [5] Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy
    Conway, KA
    Lee, SJ
    Rochet, JC
    Ding, TT
    Williamson, RE
    Lansbury, PT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) : 571 - 576
  • [6] New animal models for Parkinson's disease
    Dawson, TM
    [J]. CELL, 2000, 101 (02) : 115 - 118
  • [7] Prospects for new restorative and neuroprotective treatments in Parkinson's disease
    Dunnett, SB
    Björklund, A
    [J]. NATURE, 1999, 399 (6738) : A32 - A39
  • [8] Parkinson disease, the effect of levodopa, and the ELLDOPA trial
    Fahn, S
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (05) : 529 - 535
  • [9] α-synuclein gene haplotypes are associated with Parkinson's disease
    Farrer, M
    Maraganore, DM
    Lockhart, P
    Singleton, A
    Lesnick, TG
    de Andrade, M
    West, A
    de Silva, R
    Hardy, J
    Hernandez, D
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (17) : 1847 - 1851
  • [10] Lewy bodies and parkinsonism in families with parkin mutations
    Farrer, M
    Chan, P
    Chen, R
    Tan, L
    Lincoln, S
    Hernandez, D
    Forno, L
    Gwinn-Hardy, K
    Petrucelli, L
    Hussey, J
    Singleton, A
    Tanner, C
    Hardy, J
    Langston, JW
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (03) : 293 - 300